Project Grant R01CA296079
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $544K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Cancer Institute awarded Emory University $639,077 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop rapid quantitative amide proton transfer-weighted (APTW) magnetic resonance imaging for brain tumor characterization at 3 Tesla field strength. The work addresses clinical challenges in chemical exchange saturation transfer (CEST) MRI by refining the quasi-steady-state (QUASS) algorithm to reconstruct equilibrium CEST signals...
- The National Cancer Institute awarded Vanderbilt University Medical Center $701,332 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate MRI cytometry as a noninvasive imaging biomarker for characterizing renal masses and distinguishing benign from malignant tumors. The project applies advanced diffusion MRI technique with multicompartment biophysical modeling to generate voxelwise maps of cell size and cellularity at...
- The National Cancer Institute awarded $694,929 to Vanderbilt University Medical Center on July 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to translate MR cytometry imaging into a clinical tool for cancer detection and diagnosis. MR cytometry is a diffusion MRI-based imaging technique that non-invasively measures mean cell size in vivo. The award funds an academic-industrial partnership among Vanderbilt University Medical Center, the University of Washington...
- The National Cancer Institute awarded $400,000 to Zeest Bio Inc. on September 15, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel liver-specific positron emission tomography tracer for improved detection of metastatic tumors and assessment of liver function and biliary tract pathology. The recipient will complete preclinical testing and investigational new drug-enabling studies in preparation for first-in-human clinical trials. Current imaging...
- The National Cancer Institute awarded the University of California, Berkeley $712,375 on April 1, 2026, through the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop the ADAPT PRO system, a single, digitally programmable radiofrequency system that enables magnetic resonance imaging of any nucleus independent of or simultaneously with others. The project runs through March 31, 2031, with work performed in Berkeley, California. The ADAPT PRO system addresses a technical...
- The National Cancer Institute awarded the University of California, Davis $409,141 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop contrast-enhanced perfusion CT imaging as an alternative to current liver radioembolization workup procedures. The project addresses imaging optimization for selective internal radiation therapy (SIRT), a catheter-based treatment for liver cancer using radioactive yttrium-90 microspheres. Current clinical practice...
- The National Cancer Institute awarded Vanderbilt University Medical Center $449,969 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop novel biomarkers for diagnosing malignant pleural effusion using extracellular vesicles and non-vesicular particles derived from pleural fluid. Malignant pleural effusion affects approximately 200,000 individuals annually in the United States, with lung cancer as the most common source. Current cytologic examination...
- The National Institutes of Health National Cancer Institute awarded Vanderbilt University Medical Center $695,884 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate selective loss of HLA gene products in triple-negative breast cancer immunobiology. The research examines how tumor cells evade immune checkpoint inhibition through downregulation or deletion of MHC-I (major histocompatibility complex I) expression. Preliminary data from the recipient's...
- The National Cancer Institute awarded Yale University $607,690 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an MR-based platform for simultaneous intracellular pH (PHI) and extracellular pH (PHE) imaging in glioblastoma multiforme (GBM). The research aims to distinguish glycolytic and oxidative tumor phenotypes by measuring transmembrane pH gradients, which are larger in tumors than normal tissue and vary between metabolic phenotypes....
- The National Cancer Institute awarded Vanderbilt University $139,313 on December 17, 2025, under the Cancer Research Manpower program (CFDA 93.398) to develop small molecule inhibitors of the XPA-RPA protein interaction as a strategy to sensitize cancer cells to platinum-based chemotherapy agents and improve treatment response. The work involves fragment-based drug discovery, using NMR screening of curated small molecular fragment libraries to identify compounds that bind within the XPA-RPA...